Expertise in
7
conditions
Expertise in
7
conditions
Baptist Health Miami Cancer Institute
8900 N Kendall Dr, 
Miami, FL 

Overview

Doured Daghistani is an Oncologist in Miami, Florida. Dr. Daghistani is highly rated in 7 conditions, according to our data. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Hereditary Spherocytosis, Acute Lymphoblastic Leukemia (ALL), and Blood Clots. Dr. Daghistani is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Pediatric Hematology-Oncology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Baptist Health Miami Cancer Institute
8900 N Kendall Dr, Miami, FL 33176

Additional Areas of Focus

Dr. Daghistani has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


24 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
View 23 Less Clinical Trials
Similar Doctors
Expertise in
25
conditions
Expertise in
25
conditions

Baptist Health Miami Cancer Institute

8900 N Kendall Dr, 
Miami, FL 
 (4.9 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Manmeet Ahluwalia is an Oncologist in Miami, Florida. Dr. Ahluwalia is highly rated in 25 conditions, according to our data. His top areas of expertise are Brain Tumor, Glioblastoma, Astrocytoma, and Glioma. Dr. Ahluwalia is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions

Baptist Hospital Of Miami

8900 N Kendall Dr, 
Miami, FL 
 (4.9 miles away)
Languages Spoken:
English
Offers Telehealth

Yazmin Odia is an Oncologist in Miami, Florida. Dr. Odia is highly rated in 24 conditions, according to our data. Her top areas of expertise are Glioma, Brain Tumor, Gliomatosis Cerebri, and Astrocytoma.

Brian Slomovitz
Expertise in
15
conditions
Expertise in
15
conditions

Office

4306 Alton Rd Fl 3, 
Miami Beach, FL 
 (11.4 miles away)
Languages Spoken:
English
Offers Telehealth

Brian Slomovitz is an Oncologist in Miami Beach, Florida. Dr. Slomovitz is highly rated in 15 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy.

Frequently Asked Questions about Dr. Doured Daghistani

How do I make an appointment with Dr. Doured Daghistani?

You can book an appointment with Dr. Doured Daghistani by calling their office at 786-345-7208. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Doured Daghistani a top-rated expert for Diffuse Midline Glioma H3 K27M-Mutant?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Doured Daghistani is classified as an Advanced expert for Diffuse Midline Glioma H3 K27M-Mutant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Doured Daghistani specialize in?

While Dr. Doured Daghistani is a Oncology, they have specific expertise in Diffuse Midline Glioma H3 K27M-Mutant, Hereditary Spherocytosis, and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Doured Daghistani participate in research or clinical trials?

Yes. Dr. Doured Daghistani has published 7 articles and abstracts on conditions like Diffuse Midline Glioma H3 K27M-Mutant. You can view a list of Dr. Doured Daghistani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Doured Daghistani accept my insurance?

Dr. Doured Daghistani accepts most major insurance plans, including Aetna and AvMed. We recommend calling the office directly at 786-345-7208 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Daghistani's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 25 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile